The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma

British Journal of Haematology

Volumn 162, Issue 5, 2013, Pages 657-669

  Gu, Juan J ^a   Hernandez Ilizaliturri, Francisco J ^a   Kaufman, Gregory P ^a   Czuczman, Natalie M ^a   Mavis, Cory ^a   Skitzki, Joseph J ^a   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

B cell lymphoma; Bortezomib; Carfilzomib; Ubiquitin proteasome system

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CARFILZOMIB; ETOPOSIDE; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN BAK; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BIOLOGICAL ACTIVITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG TARGETING; HUMAN; HUMAN TISSUE; LYMPHOMA CELL; MULTIPLE MYELOMA; MYELOMA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; UPREGULATION; WESTERN BLOTTING;

B-CELL LYMPHOMA; BORTEZOMIB; CARFILZOMIB; UBIQUITIN-PROTEASOME SYSTEM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BORONIC ACIDS; CASPASE INHIBITORS; CASPASES; CELL CYCLE CHECKPOINTS; CYTOTOXICITY, IMMUNOLOGIC; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; LYMPHOMA, B-CELL; NEOPLASM PROTEINS; OLIGOPEPTIDES; PROTEASOME INHIBITORS; PYRAZINES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84881665067     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12452     Document Type: Article

References (34)

1. Adams, J. (2004) The proteasome: a suitable antineoplastic target. Nature Reviews Cancer, 4, 349-360.
2. Alsina, M., Trudel, S., Furman, R.R., Rosen, P.J., O'Connor, O.A., Comenzo, R.L., Wong, A., Kunkel, L.A., Molineaux, C.J. & Goy, A. (2012) A Phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clinical Cancer Research, 18, 4830-4840.
3. Arastu-Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J. & Kirk, C.J. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical Cancer Research, 17, 2734-2743.
4. Barr, P., Fisher, R. & Friedberg, J. (2007) The role of bortezomib in the treatment of lymphoma. Cancer Investigation, 25, 766-775.
5. Bhalla, S., Balasubramanian, S., David, K., Sirisawad, M., Buggy, J., Mauro, L., Prachand, S., Miller, R., Gordon, L.I. & Evens, A.M. (2009) PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical Cancer Research, 15, 3354-3365.
6. Bil, J., Winiarska, M., Nowis, D., Bojarczuk, K., Dabrowska-Iwanicka, A., Basak, G.W., Sulek, K., Jakobisiak, M. & Golab, J. (2010) Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. Blood, 115, 3745-3755.
7. Boccadoro, M., Morgan, G. & Cavenagh, J. (2005) Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell International, 5, 18.
8. Brem, E.A., Thudium, K., Khubchandani, S., Tsai, P.C., Olejniczak, S.H., Bhat, S., Riaz, W., Gu, J., Iqbal, A., Campagna, R., Knight, J., Mavis, C., Hoskin, P., Deeb, G., Gibbs, J.F., Fetterly, G., Czuczman, M.S. & Hernandez-Ilizaliturri, F.J. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology, 153, 599-611.
9. Canfield, S.E., Zhu, K., Williams, S.A. & McConkey, D.J. (2006) Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Molecular Cancer Therapeutics, 5, 2043-2050.
10. Cavaletti, G. & Jakubowiak, A.J. (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leukaemia & Lymphoma, 51, 1178-1187.
11. Czuczman, M.S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J. & Hernandez-Ilizaliturri, F.J. (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research, 14, 1561-1570.
12. Denlinger, C.E., Rundall, B.K., Keller, M.D. & Jones, D.R. (2004) Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Annals of Thoracic Surgery, 78, 1207-1214; discussion 1207-1214.
13. Dick, L.R. & Fleming, P.E. (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discovery Today, 15, 243-249.
14. Dunleavy, K., Pittaluga, S., Czuczman, M.S., Dave, S.S., Wright, G., Grant, N., Shovlin, M., Jaffe, E.S., Janik, J.E., Staudt, L.M. & Wilson, W.H. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood, 113, 6069-6076.
15. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. & Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667-675.
16. Groll, M., Huber, R. & Potts, B.C. (2006) Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. Journal of the American Chemical Society, 128, 5136-5141.
17. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
18. Jain, S., Diefenbach, C., Zain, J. & O'Connor, O.A. (2011) Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evidence, 6, 43-57.
19. Kane, R.C., Dagher, R., Farrell, A., Ko, C.W., Sridhara, R., Justice, R. & Pazdur, R. (2007) Bortezomib for the treatment of mantle cell lymphoma. Clinical Cancer Research, 13, 5291-5294.
20. Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan-Khan, A.A. & Orlowski, R.Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281-3290.
21. Ning, Y.M., He, K., Dagher, R., Sridhara, R., Farrell, A.T., Justice, R. & Pazdur, R. (2007) Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park), 21, 1503-1508; discussion 1511, 1513, 1516 passim.
22. O'Connor, O.A. (2005) Targeting histones and proteasomes: new strategies for the treatment of lymphoma. Journal of Clinical Oncology, 23, 6429-6436.
23. O'Connor, O.A., Stewart, A.K., Vallone, M., Molineaux, C.J., Kunkel, L.A., Gerecitano, J.F. & Orlowski, R.Z. (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clinical Cancer Research, 15, 7085-7091.
24. Olejniczak, S.H., Hernandez-Ilizaliturri, F.J., Clements, J.L. & Czuczman, M.S. (2008) Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical Cancer Research, 14, 1550-1560.
25. Olejniczak, S.H., Blickwedehl, J., Belicha-Villanueva, A., Bangia, N., Riaz, W., Mavis, C., Clements, J.L., Gibbs, J., Hernandez-Ilizaliturri, F.J. & Czuczman, M.S. (2010) Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood, 116, 5605-5614.
26. Parlati, F., Lee, S.J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J.B., Micklem, D.R., Ruurs, P., Sylvain, C., Lu, Y., Shenk, K.D. & Bennett, M.K. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood, 114, 3439-3447.
27. Perez-Galan, P., Roue, G., Villamor, N., Montserrat, E., Campo, E. & Colomer, D. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 107, 257-264.
28. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
29. Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. & Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, 2105-2112.
30. Vij, R., Wang, M., Kaufman, J.L., Lonial, S., Jakubowiak, A.J., Stewart, A.K., Kukreti, V., Jagannath, S., McDonagh, K.T., Alsina, M., Bahlis, N.J., Reu, F.J., Gabrail, N.Y., Belch, A., Matous, J.V., Lee, P., Rosen, P., Sebag, M., Vesole, D.H., Kunkel, L.A., Wear, S.M., Wong, A.F., Orlowski, R.Z. & Siegel, D.S. (2012) An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood, 119, 5661-5670.
31. de Vos, S., Goy, A., Dakhil, S.R., Saleh, M.N., McLaughlin, P., Belt, R., Flowers, C.R., Knapp, M., Hart, L., Patel-Donnelly, D., Glenn, M., Gregory, S.A., Holladay, C., Zhang, T. & Boral, A.L. (2009) Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. Journal of Clinical Oncology, 27, 5023-5030.
32. Weniger, M.A., Rizzatti, E.G., Perez-Galan, P., Liu, D., Wang, Q., Munson, P.J., Raghavachari, N., White, T., Tweito, M.M., Dunleavy, K., Ye, Y., Wilson, W.H. & Wiestner, A. (2011) Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clinical Cancer Research, 17, 5101-5112.
33. Wright, J.J. (2010) Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clinical Cancer Research, 16, 4094-4104.
34. Younes, A., Pro, B. & Fayad, L. (2006) Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood, 107, 1731-1732.